ArticleAdvances in therapy2026
Patient and Physician Experiences in Immune Thrombocytopenia.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune thrombocytopenia (ITP) is a rare autoimmune disease that results in low platelet counts and an increased risk of spontaneous bleeding due to impaired blood clotting. Several therapeutic approaches can be used to treat patients with ITP. However, many patients either lose response in the long term or are unable to maintain a response after treatment discontinuation, necessitating chronic treatment and multiple lines of therapy. Here, two patients with ITP share their experience, each providing a firsthand description of their ITP diagnosis, symptoms, management, and perspectives on the future. These stories are complemented by a clinical review of ITP pathophysiology, symptoms, and treatments presented by two expert hematologists who care for patients with ITP. The physician perspective reinforces the challenges faced by patients in everyday life and highlights the remaining areas of concern regarding the treatment of chronic ITP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.